The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy
Authors' conclusion
Among younger patients who underwent SG at our institution more than 10 years ago, patients currently taking adjuvant semaglutide and/or tirzepatide demonstrated significantly better long-term weight loss than patients not taking adjuvant AOMs.
Study context
- Population
- Adults who underwent sleeve gastrectomy (SG) before 45 years old, Jan 2013–Dec 2014, with BMI data ≥9.5 years after SG; conversion to RYGB excluded; single United States (US) institution
- Participants
- 111 adults
- Exposure
- Adjuvant semaglutide and/or tirzepatide vs no adjuvant AOMs after SG
- AOMsn = 44
- No AOMsn = 67reference
- Outcome
- Longitudinal weight loss (%TWL)
- Follow-up
- Most recent visit (mean ≈10.6–10.7 years after SG)
Methodological detailssingle-institution
- Single-institution
Main finding
As reported in the abstract
Mean %TWL · most recent visit
| Group | Value | Mean years after SG |
|---|---|---|
| AOMs | mean 25.7% | 10.7 |
| No AOMs | mean 14.1% | 10.6 |
Value
AOMsmean 25.7%
No AOMsmean 14.1%
Mean years after SG
AOMs10.7
No AOMs10.6
- AOMs vs No AOMs: P < 0.001
Observational data: associations, not effects.
Further findings
AOM timing
- Mean time from SG to AOM start (years)
- 7.6
- Mean duration of AOM use at most recent visit (years)
- 3.0
Weight loss trajectory before AOM initiation
- Groups had similar weight loss trajectories prior to adjuvant medications
Original publication
The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy. Int J Obes (Lond). Published 30 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →